A public-health message that once seemed too simple to question—“always finish your antibiotics”—is colliding with a more complicated reality. New research from scientists at the University of Utah Health and the University of Alabama at Birmingham suggests that most American adults still believe completing an entire prescribed course is always the safest choice, even when symptoms have disappeared and current evidence supports a shorter treatment. The national survey found that nearly 90% of respondents had heard and accepted the long-standing advice, revealing how deeply earlier antibiotic campaigns continue to shape public expectations.
The findings do not mean that patients should stop taking antibiotics whenever they begin to feel better. Instead, they highlight a crucial distinction: the appropriate duration of treatment depends on the infection, the drug, the patient’s health and the strength of the available evidence. Antibiotics are designed to eliminate or suppress bacterial pathogens, but the exposure also affects the body’s normal microbial communities. Unnecessarily prolonged treatment can increase the likelihood of adverse effects, including gastrointestinal symptoms, allergic reactions and secondary infections, while creating additional opportunities for antibiotic-resistant bacteria to survive and multiply.
The study, published in Open Forum Infectious Diseases, surveyed 1,475 adults across the United States about how they would respond to different recommendations for antibiotic treatment. Participants were asked to compare a three- to five-day course for pneumonia, consistent with current clinical guidance in many cases, with a course lasting a week or longer, reflecting older recommendations. Approximately 60% said they would feel more comfortable taking the longer regimen, despite evidence that shorter treatment can be equally effective and less likely to cause harm for appropriately selected patients with common bacterial respiratory infections.
That preference was strongly connected to the familiar instruction to complete the entire prescription. About 88% of respondents reported that they had heard and agreed with the “always finish your antibiotics” message. Clinicians were the most common source, although many participants had also encountered the advice through public-health campaigns. Such messaging was developed for understandable reasons. Earlier concerns focused on patients stopping treatment too soon, potentially allowing surviving bacteria to rebound and causing infection to return. At the time, a clear universal rule appeared to offer a practical way to encourage adherence and prevent self-directed medication changes.
However, antibiotic science has changed as researchers have accumulated data from randomized clinical trials, observational studies and antimicrobial-resistance surveillance. For some infections, treatment courses that are shorter than historical standards produce the same clinical outcomes as longer regimens. The goal is not to expose the body to antibiotics for as many days as possible, but to provide enough drug, for enough time, to control the pathogen while limiting toxicity and ecological damage. Every additional dose can exert selective pressure on bacterial populations, favoring organisms that carry or acquire mechanisms capable of surviving antibiotic exposure. Those mechanisms may include drug-inactivating enzymes, altered cellular targets, reduced membrane permeability or molecular pumps that expel antibiotics from bacterial cells.
The evidence is not uniform across diseases. Pneumonia may often be treated effectively with a shorter course when a patient is improving and the infection meets specific clinical criteria, but other conditions require considerably longer therapy. Tuberculosis, for example, generally demands prolonged treatment because the bacterium can persist in difficult-to-reach tissues and may exist in physiological states that make it less vulnerable to drugs. Treatment duration may also change according to the infectious organism, the site and severity of disease, immune status, complications and the patient’s response. A shorter course that is appropriate for one person or infection could be inadequate for another.
This variation creates a communication problem. Patients often want a simple rule that can be applied without ambiguity, while infectious-disease treatment increasingly relies on decisions tailored to individual circumstances. The survey indicates that when people are presented with a shorter course, they may interpret it as incomplete or risky rather than as the result of improved evidence. The researchers therefore argue that clinicians and public-health organizations should replace universal slogans with clearer explanations: some infections need longer treatment, some need shorter treatment and recommendations can change as clinical trials reveal how to balance effectiveness against harm.
Alistair Thorpe, a research assistant professor of population health sciences at University of Utah Health and the study’s first author, said the historical message was once strongly endorsed by major health organizations and clinicians. Growing evidence now shows that it is not appropriate for every condition. He and his colleagues recommend that patients discuss the planned duration, the reason for the selected course and the circumstances under which treatment should be stopped or reassessed. This conversation is especially important because symptoms alone do not always reveal whether bacteria have been eliminated, whether an illness was bacterial in the first place or whether a complication has developed.
The researchers describe the shift in antibiotic guidance as a sign of progress rather than inconsistency. Medical recommendations are expected to evolve when better evidence becomes available, but changes are difficult to communicate when older advice has been repeated for decades. The new findings suggest that successful antibiotic stewardship will require more than prescribing fewer doses. It will also require rebuilding trust around the idea that a shorter prescription can represent a carefully tested treatment strategy, not undertreatment. For patients, the central message is not to abandon a prescription based on feeling better, but to follow an individualized plan developed with a clinician—one that reflects the infection, the patient and the latest evidence on how to use antibiotics safely.
Subject of Research: People
Article Title: US Adults’ Perspectives on Antibiotic Durations and Adherence to Therapy for Common Bacterial Respiratory Infections: A National Survey
News Publication Date: 21-Jul-2026
Web References: https://academic.oup.com/ofid/article/13/7/ofag407/8734928
References: Open Forum Infectious Diseases; University of Utah Health; American Heart Association; University of Alabama at Birmingham
Image Credits: Jen Pilgreen / University of Utah Health
Keywords: Antibiotics, antibiotic duration, antibiotic resistance, antimicrobial stewardship, pneumonia, bacterial infections, public health, medical communication, infectious diseases, survey research
